TSS
PSTX

Two Sigma Securities’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Two Sigma Securities’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,105
Closed -$24.1K – 3722
2023
Q3 		$24.1K Buy
+10,105
New +$21.2K ﹤0.01% 2552

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Two Sigma Securities's PSTX Position: Q4 2023 in Review

Two Sigma Securities sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q4 2023, closing a stake of 10,105 shares — an estimated $24.1K sold.

Two Sigma Securities first reported a position in PSTX in Q3 2023 and held it in 1 quarter. The position peaked at $24.1K in Q3 2023. 91 funds tracked by Wall St. Rank hold PSTX as of Q4 2023.

  • Two Sigma Securities reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Securities sold 10,105 Poseida Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $24.1K.
  • Two Sigma Securities first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • Two Sigma Securities's Poseida Therapeutics, Inc. Common Stock position peaked at $24.1K in Q3 2023.
  • 91 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Two Sigma Securities's 13F filing for Q4 2023, filed 14 Feb 2024.